MicroPort®
微创心通

MicroPort CardioFlow Medtech Corporation
微创心通医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2160)

INSIDE INFORMATION

DELAY IN PUBLICATION OF THE INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2026; POSTPONEMENT OF DATE OF BOARD MEETING; AND SUSPENSION OF TRADING

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of MicroPort CardioFlow Medtech Corporation (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 and Rule 13.49(6) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the Company's announcement dated August 2, 2026 regarding the discloseable transactions in relation to lease agreements entered into by Shanghai MicroPort CardioFlow Medtech Co., Ltd. ("**MP CardioFlow**") and MicroPort Soaring CRM (Shanghai) Co., Ltd. ("**MicroPort CRM Shanghai**") with Shanghai BlueOrange Capital Corp. (the "**Landlord**") (a subsidiary of Real & Realistic Foundation Limited ("**R&R**")) (the "**Lease Agreements Announcement**"). In this announcement, unless the context otherwise requires, the following expressions shall have the meanings set out in the Lease Agreements Announcement.

Delay in Publication of the Company's 2026 Interim Results

Pursuant to Rule 13.49(6) of the Listing Rules, the Company is required to publish a preliminary announcement in respect of the results of the Group for the six months ended June 30, 2026 (the "**2026 Interim Results**") not later than two months after the end of that period, i.e. on or before August 31, 2026. Where the Company is unable to publish the 2026 Interim Results within the required time, it must publish an announcement containing: (i) a full explanation for its inability to make an announcement based on unaudited financial statements; and (ii) the expected date of publication.

In compliance with Rule 13.49(6) of the Listing Rules, the Board wishes to announce that the publication of the 2026 Interim Results and the 2026 Interim Report is expected to be delayed, as the Board considers that the Company requires additional time to : (i) ascertain the background of the Landlord and its associates and its relationship with the Company; (ii) assess the commercial reasonableness of the lease terms, including but not limited to the lease pricing and security deposits; and (iii) evaluate the reasonableness and the appropriate accounting treatment of additional renovation costs incurred in connection with the lease (the "**Matters**").

The Board acknowledges that the delay in publication of the 2026 Interim Results may constitute non-compliance with Rule 13.49(6) of the Listing Rules. The Company will publish further announcement(s) in due course to inform the Shareholders and potential investors of (i) the rescheduled date of the meeting of the Board to consider and approve the 2026 Interim Results; (ii) the expected date of the publication of the 2026 Interim Results; and (iii) any material development on the Matters as and when appropriate in accordance with the Listing Rules.

Postponement of Board Meeting

Reference is made to the announcements of the Company dated August 14, 2026 and August 26, 2026, in relation to the meeting of the board of directors of the Company (the "**Board Meeting**"), for the purpose of, among other matters, considering and approving the consolidated interim results of the Group for the six months ended June 30, 2026 and its publication, and considering the payment of an interim dividend, if any. Due to the reasons mentioned above, the Board hereby announces that the Board Meeting will be postponed accordingly until the Matters being properly resolved.

Suspension of Trading

Pursuant to Rule 13.50 of the Listing Rules, the Stock Exchange will normally require suspension of trading in an issuer's securities if an issuer fails to publish its interim results in accordance with Rule 13.49 of the Listing Rules. The suspension will normally remain in force until the issuer publishes an announcement containing the requisite financial information. The Board hereby announces that, in accordance with Rule 13.50 of the Listing Rules and at the request of the Company, trading in the shares of the Company on the Stock Exchange will be suspended with effect from 9:00 a.m. on Tuesday, September 1, 2026 and shall remain suspended until the publication of the 2026 Interim Results and any other inside information that may be required to be disclosed under the Listing Rules.

The Company will make further announcement(s) in due course to inform its Shareholders and potential investors of any information update. The Board wishes to emphasize that the business operations of the Group remain normal, and the Matters relates to the review and disclosure of financial information rather than the Group's operations. The Shareholders and potential investors are reminded to exercise caution when dealing in the shares of the Company.

By Order of the Board
MicroPort CardioFlow Medtech Corporation
Brian Chang
Chairman

Shanghai, PRC, August 31, 2026

As of the date of this announcement, the executive Directors are Mr. Chen Guoming, Mr. Zhang Ruinian and Mr. Philippe Wanstok, the non-executive Directors are Dr. Brian Chang and Mr. Deng Aoyi, and the independent non-executive Directors are Mr. Jonathan H. Chou, Ms. Sun Zhixiang, Dr. Hu Bingshan and Mr. Mao Junxiang.